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Abstract
Background:  Transforming growth factor-β (TGFβ) plays an important role in late-stage
carcinogenesis by stimulating invasive behavior of cancer cells, promoting neo-angiogenesis and by
helping cancer cells to escape surveillance by the immune system. It also supports colonization of
the bone by metastatic breast cancer cells by increasing expression of osteolytic parathyroid
hormone-related protein (PTHrP). Interfering with TGFβ signalling may thus weaken the malignant
properties of cancer cells. We investigated to what extent two inhibitors, SB-202190 and SB-
203580, interfere with TGFβ-signalling in invasive MDA-MB-231 breast cancer cells. These
compounds, formerly used as p38-MAPK-specific inhibitors, were recently also demonstrated to
inhibit TGFβ type I receptor kinase.
Results:  Our results show that these inhibitors delay the onset of TGFβ-induced nuclear
accumulation of Smad3 and reduces its amplitude. This effect was accompanied by a strong
reduction in TGFβ-responsivess of the slow-responder genes pthrp, pai-1 and upa, while the
reactivity of the fast-responder gene smad7 to TGFβ remained almost unchanged. Neither was the
TGFβ response of the fast-responder ese-1/esx gene, whose expression we found to be strongly
downregulated by TGFβ, affected by the inhibitors.
Conclusion: The data show that SB-202190 and SB-203580 suppress TGFβ-dependent activation
of genes that are important for the acquisition of invasive behavior, while having no effect on the
expression of the natural TGFβ inhibitor Smad7. This suggests that these compounds are potent
inhibitors of malignant behavior of cancer cells.
Background
Malignant tumor cells frequently show deregulation and
hyperactivation of signalling pathways, one of which is
represented by the TGFβ signal transduction pathway [1].
TGFβ has been shown to potently inhibit proliferation of
most epithelial, endothelial and hematopoietic cells [2].
However, during tumor progression malignant cells may
become refractory to TGFβ-mediated cell cycle arrest. In
later stages of tumorigenesis, TGFβ can act as a stimulator
of invasion and metastasis [3] acting directly on the tumor
Published: 19 March 2003
Molecular Cancer 2003, 2:20
Received: 23 January 2003
Accepted: 19 March 2003
This article is available from: http://www.molecular-cancer.com/content/2/1/20
© 2003 Lindemann et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in 
all media for any purpose, provided this notice is preserved along with the article's original URL.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/20
Page 2 of 10
(page number not for citation purposes)
cells or inducing angiogenesis and facilitating local and
systemic immunosuppression, respectively [4]. For exam-
ple, TGFβ may stimulate the expression of proteases such
as uPA, MMP-3 or MMP-9, enzymes frequently overex-
pressed in invasive tumor cells [5,6].
TGFβ signals through a heteromeric receptor complex of
type II and type I receptor serine-threonine kinases, which
activates the downstream Smad signal transduction path-
way [7]. After TGFβ binding to the receptor complex, the
TGFβ type II receptor kinase phosphorylates TGFβ type I
receptor which inititates the downstream response by
phosphorylating receptor-regulated Smads (R-Smads),
such as Smad2 and Smad3. By forming a multimeric com-
plex with the Co-Smad Smad4, activated R-Smads translo-
cate to the nucleus and induce transcriptional modulation
of target genes [8].
Breast cancer cells frequently metastasize to bone causing
bone destruction and hypercalcemia [9]. Parathyroid hor-
mone-related protein (PTHrP), secreted by these cells, is a
major mediator of the osteolytic process [10]. Osteolysis
leads to the release of TGFβ which, in turn, further induces
PTHrP expression [11]. Other tumor-relevant genes, such
as pai-1 or upa, can also be activated by TGFβ.
Hence, downregulation of TGFβ mediated gene expres-
sion may counteract malignancy of cancer cells. In this
study, we investigated whether two small molecules, SB-
203580 and SB-202190, could be used to downmodulate
TGFβ-induced transcriptional activation of TGFβ target
genes. In the past, these compounds have been widely
used as specific p38 inhibitors [12] and their inhibitory
action has been well documented [13–15]. However, re-
cent results show that, in a comparable concentration
range they inhibit the serine/threonine kinase activity of
TGFβ type I receptor preventing phosphorylation of R-
Smads [16–18].
Here we show that, in the highly invasive breast cancer
cell line MDA-MB-231, the SB-202190 and SB-203580 in-
hibitors negatively altered Smad3 nuclear entry upon
TGFβ stimulation. This resulted in a reduced response of
TGFβ-inducible genes to TGFβ. The degree of inhibition
varied tremendously depending on the particular gene
analyzed.
Results
SB-202190 and SB-203580 downregulate transcription 
from TGFβ-responsive genes
Plasminogen activator inhibitor-1 (PAI-1) and PTHrP are
known target genes of TGFβ signalling. We have previous-
ly demonstrated that TGFβ upregulates PTHrP and PAI-1
RNA levels in MDA-MB-231 cells [19]. TGFβ affected
PTHrP expression primarily by increasing the level of the
promoter P3-specific transcript [19]. Quantitative PCR
analysis using primers allowing the detection of PTHrP P3
and PAI-1 transcripts indicated that incubation of MDA-
MB-231 cells with SB-202190 and SB-203580 greatly in-
hibited TGFβ-induced increase in PTHrP and, to a lesser
extent, PAI-1 mRNA levels (Fig. 1A,1B).
Next, we examined whether inhibitory effects of these
compounds can also be seen on the PAI-1 promoter in
transient transfection assays. By using 3TP-Luc as a report-
er plasmid we observed that TGFβ increased the activity of
3TP-Luc by approximately 3.5-fold (Fig. 1C,1D). Preincu-
bation with the SB inhibitors reduced this activation al-
most to basal levels.
These data suggest that SB-202190 and SB-203580 inhibit
TGFβ-stimulated gene expression at least in part by down-
regulating transcription.
SB-202190 and SB-203580 deregulate TGFβ-induced 
Smad3 nuclear accumulation
It has recently been shown that SB-202190 and SB-
203580 are able to inhibit TGFβ-induced phosphoryla-
tion of Smad3 by the TGFβ-receptor I kinase (ALK5) and
to interfere with nuclear localization of Smad3 [17]. Nu-
clear translocation of Smad3 results directly from TGFβ-
induced Smad3 phosphorylation and is, therefore, a
measure of the activation status of ALK5. We wanted to
know to what extent SB-202190 and SB-203580 interfere
with TGFβ-dependent Smad3 nuclear import in the inva-
sive MDA-MB-231 breast cancer cell line. We prepared nu-
clear and whole cell extracts from cells treated with TGFβ
with or without preincubation of one of the SB inhibitors
and analyzed those extracts for reactivity to a Smad2,3-
specific antibody by Western blot analysis. This antibody
primarily interacts with Smad3, but, to some extent, it is
also able to recognize Smad2. Based on Northern blot hy-
bridization data, Smad3, but not Smad2, is expressed in
MDA-MB-231 cells [21]. Hence, the data presented in Fig.
2 show the abundance of Smad3 in the nuclear and in the
whole cell extracts. We found that preincubation of cells
with either SB-202190 or SB-203580 decreased the level
of nuclear Smad3 in the presence of TGFβ (Fig. 2A),
whereas the total Smad3 protein level, as assayed in whole
cell extracts, was not altered.
Next, we studied the time-course of TGFβ-induced Smad3
nuclear entry in the presence or absence of SB-203580.
MDA-MB-231 cells were stimulated with TGFβ and har-
vested after various time points. Nuclear extracts were pre-
pared and subjected to Western blotting analysis using an
anti-Smad3 antibody. Stimulation of the cells with TGFβ
led to a rapid increase in nuclear Smad3 protein within 15
minutes and this level remained constant for 2 hours.
Thereafter it started to decrease. However, pretreatment ofMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/20
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the cells with 20 µM SB-203580 perturbed Smad3 nuclear
accumulation, reducing the amount of Smad3 entering
the nucleus and shifting the peak level of nuclear Smad3
to a later time point.
Other kinase inhibitors fail to inhibit TGFβ mediated 
Smad3 nuclear entry
We next explored the possibility that the MEK1/2 inhibi-
tor PD98059 and the Rho-associated kinase inhibitor Y-
27632 might also interfere with Smad3 nuclear entry.
However, both agents failed to reproduce the effect of the
SB inhibitors as TGFβ-induced nuclear accumulation of
Smad3 was not affected by these inhibitors (Fig. 2C). We
also used the protein kinase C (PKC) activator phorbol-
12-myristate-13-acetate (PMA) (Fig. 2C), which appeared
to enhance the amount of both basal and TGFβ-induced
nuclear Smad3, a phenomenon that has been reported
earlier [22].
Figure 1
Upregulation of TGFβ target genes is diminished by SB-202190 and SB-203580. A and B, Real-time RT-PCR measurement of 
PTHrP P3 promoter and PAI-1 transcripts. Cells were incubated with 5 ng/ml TGFβ for four hours. C and D, Transient trans-
fection assays using the 3TP-Luc reporter plasmid. Cells were treated with TGFβ for seven hours, lysed and luciferase activity 
was measured and normalized to β-galactosidase activity. Cells were incubated with DMSO or the SB-202190 (A+C, 1–10 µM) 
and SB-203580 (D+E, 5–20 µM) 45 min prior to TGFβ addition. Fold activations relative to untreated samples were calculated.
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Figure 2
SB inhibitors deregulate TGFβ induced Smad3 nuclear accumulation. A, Western Blotting analysis of whole cell and nuclear 
extracts of cells treated with 5 ng/ml TGFβ for 30 min after 45 min preincubation with DMSO or SB-202190 (10 µM) and SB-
203580 (20 µM). Smad3 protein was detected using a mouse monoclonal Smad3 antibody from Santa Cruz. B, Western Blot-
ting analysis as in A using nuclear extracts of cells stimulated with TGFβ for the indicated times after 45 min preincubation with 
DMSO or SB-203580 (20 µM). C, same as in A with inhibitors SB-203580 (20 µM), PD98059 (40 µM), Y-27632 (20 µM) or 
PMA (25 nM), respectively. Coomassie staining and reprobing of blots with a control antibody (PKCα) ensured equal protein 
loading for all lanes (not shown).
WCE
NE
αSmad3
TGFβ1 -+-+-+
SB202190
SB203580 ----+ +
--+ +--
SB203580
0 15 30 60 120 180 240 0 15 30 60 120 180 240
WCE
NE
αSmad3
TGFβ1 (min)
mock
NE
-+-+-+-+-+
αSmad3
TGFβ1
Inhibitor SB - PD Y PMA
C
B
AMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/20
Page 5 of 10
(page number not for citation purposes)
TGFβ target genes respond differentially to inhibition of 
Smad3 nuclear import
The delayed TGFβ-mediated entry of Smad3 into the nu-
cleus in the presence of SB-203580 prompted us to exam-
ine the effect of SB-203580 on TGFβ-induced gene
expression in a time-course experiment. We isolated total
RNA from the same cell suspension that was used to pre-
pare nuclear extracts for time-course analysis in Fig. 2B.
cDNA was synthesized and subjected to quantitative RT-
PCR in order to measure the transcript levels of several
TGFβ target genes. The genes being examined were divid-
ed into two groups: I, known TGFβ target genes: pai-1,
smad7, c-myc, upa and pthrp (Fig. 3A,3B,3C,3D,3E) and II,
ets family genes: ets-1, ets-2 and ese-1/esx. Smad7 was of
particular interest as it belongs to the inhibitory Smads,
which can counteract TGFβ-induced gene activation [23].
The response of the smad7 gene to TGFβ is unusually rapid
[24] which is believed to stem from the peculiar nature of
the Smad7 promoter that contains a "perfect" Smad bind-
ing site [25]. Another inhibitory Smad protein is Smad6.
We have not analyzed the expression of this protein, since
it preferentially inhibit bone morphogenetic protein
(BMP)-induced expression [26]. In addition, Smad6
shows varying effects on TGFβ signalling [27]. Nor were
TGFβ-responsive genes, such as p21, studied that are in-
volved in cell cycle regulation. Such genes are important
targets at early-stage carcinogenesis, where TGFβ has a tu-
mor-suppressive rather than a tumor-promoting function
[28]. In addition, e.g. p21 protein is not dectable in MDA-
MB-231 cells [29].
Of group I, pai-1, pthrp  and upa  mRNAs were induced
upon TGFβ treatment reaching maximum activation with-
in three hours. As expected, the smad7 transcript was fully
upregulated much earlier, after approximately 60 min.
The c-myc gene has been reported to be unresponsive to
TGFβ signal transduction in MDA-MB-231 cells [24]. We
also measured the effect of TGFβ on c-myc RNA and con-
firmed these results as SB-203580 or control treatment
failed to significantly modulate c-myc transcript levels. The
inhibitory effect of SB-203580 showed remarkable varia-
tion among the genes examined. The rapid induction of
smad7 mRNA was basically unaffected by SB-203580; this
could possibly explained by a lower amout of Smad3 nec-
essary to activate the Smad7 promoter. TGFβ induced pai-
1 mRNA was reduced to approximately 50% by the SB in-
hibitor, whereas TGFβ-mediated expression of PTHrP and
uPA was highly sensitive to SB-203580 treatment. SB-
203580 downmodulated expression of the latter genes to
almost basal levels. Two ets genes, ets1 and ets2, were also
affected by TGFβ and SB-203580 (Group II, Fig. 3F,3G).
We observed that ets1 and ets2 transcript levels were slight-
ly upregulated when cells were incubated with TGFβ and
that this increase was partly inhibited by SB-203580. The
other ets gene that we tested was ese-1/esx, a recently char-
acterized member of the ets gene family, originally identi-
fied in epithelial cells [30]. Ese-1/Esx has been found to
regulate the expression of TGFβ type II receptor [31]. We
could show for the first time that the level of the Ese-1/Esx
transcript was strongly downregulated in the presence of
TGFβ. The negative TGFβ effect on Ese-1/Esx expression
could not be inhibited by SB-203580.
Discussion
Evidence has been accumulated that TGFβ promotes late-
stage tumorigenesis by stimulating angiogenesis and inva-
sive behaviour of tumor cells, enhancing immunosup-
pression and supporting epithelial-mesenchymal
transition of cancer cells [4]. Furthermore, TGFβ is be-
lieved to be part of a vicious circle in bone metastases as it
gets released from osteoclast-degraded bone substance
and subsequently stimulates PTHrP gene expression in
nearby metastatic cancer cells which in turn leads to an ac-
tivation of osteoclastic bone resorption [11]. Therefore, it
is of great interest to understand in more detail the molec-
ular aspects of TGFβ-mediated gene expression in meta-
static breast cancer cells and to explore ways to interfere
with this tumorigenic signalling.
Here we report that two small molecules, SB-202190 and
SB-203580, diminished TGFβ-induced expression of
TGFβ target genes which was accompanied by a perturba-
tion of TGFβ-mediated Smad3 nuclear accumulation, a
crucial step in TGFβ signal transduction. Using SB-
203580, we found that not only was the total level of nu-
clear Smad3 in the presence of TGFβ reduced, but also
that the nuclear entry of Smad3 was delayed and less pro-
longed. Interestingly, treating cells with TGFβ for 60 min
yielded a similar amount of Smad3 in the nucleus, irre-
spective of whether SB-203580 was present or not. How-
ever, when the time of TGFβ treatment was reduced to 15
min or prolonged to 180 or 240 min, SB-203580 had a
tremendous effect on Smad3 translocation to the nucleus.
The altered kinetic of TGFβ-dependent Smad3 nuclear en-
try as induced by SB-203580 coincided with the efficacy
by which this agent repressed the activity of the different
TGFβ target genes. Fast TGFβ responder genes, such as
smad7, whose maximum activation by TGFβ was reached
after 60 min, was only slightly affected by SB-203580,
while slow responders, such as pai-1, pthrp or upa, that
showed peak activation after 180–240 min, were very sen-
sitive to the repressive effect of SB-203580. The strongest
effect of SB-203580 was found on the TGFβ-dependent
expression of pthrp and upa. In these cases, the inhibitor
completely eliminated responsiveness to TGFβ.
How could these differential effect of SB-203580 on
TGFβ-induced gene expression be explained? It is clear
that the smad7 gene expression is regulated by TGFβ in a
Smad3/4-dependent manner [32] as it was found for theMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/20
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Figure 3
TGFβ target genes respond differentially to SB-203580. Real-time RT-PCR analyses of mRNA derived from MDA-MB-231 cells 
treated with TGFβ for 15, 30, 60, 120, 180 and 240 min. Filled line indicates TGFβ-induced activation in the absence of SB-
203580, dotted line represents activation by TGFβ in the presence of this inhibitor. Relative transcript level was calculated by 
normalizing transcript levels in induced relative to uninduced samples. A-E, known TGFβ target genes. F-H, ets family 
members.
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pthrp and the pai-1 gene [19,33]. However, the Smad3 re-
sponsive elements are different. The smad7 gene contains
a perfect palindromic Smad binding element (GTCTA-
GAC) while the pai-1  and the pthrp  promoters harbor
AGAC tandem repeats [19,33] which binds Smad proteins
less efficiently [34]. The upa gene contains only an AP1-
binding site which resembles the Smad3/4-responsive
AGAC motif [35]. A weaker binding site could require
Smad3 to be present at higher concentrations for efficient
binding and would make TGFβ-dependent transcription
from a gene more vulnerable to reduced nuclear accumu-
lation of the Smad3 protein. TGFβ-induced stabilization
of the mRNA may also be important for the sensitivity to
SB-203580. TGFβ has been shown also to stabilize the
mRNA of the smad7 gene [25], while stabilization of RNA
does not play a major role in regulation of the pthrp gene
in MDA-MB-231 cells [19]. In addition, SB-203580 also
inhibits p38 activity which has been shown to play a role
in TGFβ signalling [36–41]. Hence, several factors could
be responsible for the differential sensitivity of TGFβ-re-
sponsive genes to SB-203580.
Members of the Ets family of transcription factors share a
unique DNA binding domain, the Ets domain, and have
been shown to activate a large number of genes [42,43]
and to be involved in a number of physiological and
pathophysiological processes [44]. There has been
accumulating evidence that Ets proteins play an impor-
tant part for the invasive program of cells, particularly by
stimulating the expression of protease genes [45,46]. Ets1
and Ets2 are overexpressed in a variety of tumors, includ-
ing breast carcinomas ([44] and references therein). Fur-
thermore, our previous work has shown that, in invasive
breast cancer cells, Ets proteins activate the PTHrP P3 pro-
moter in cooperation with Smad3 [19]. In this context it
is interesting to note that TGFβ signalling seemed to target
the ets-1 and ets-2 gene (Fig. 3F,3G). Analysis of the hu-
man ets-1 promoter sequence revealed that it contains el-
ements similar to TGFβ-responsive sites in other
promoters (R. Lindemann, unpublished observation).
We present data showing that TGFβ downregulated the
Ese-1/Esx transcript, a novel and yet unpublished finding.
Ese-1/Esx is a member of the Ets transcription factor fam-
ily and is expressed mainly in epithelial tissue [30]. Its ex-
pression has been detected during mammary gland
development and breast tumorigenesis [47,48]. It is note-
worthy that Ese-1/Esx is a potential transcriptional regula-
tor of the TGFβ type II receptor [31] and overexpression of
Ese-1/Esx in non-invasive cells leads to a reduction in cell
growth in the presence of TGFβ, presumably because of an
increased TGFβ type II receptor level [49]. It is interesting
that TGFβ-dependent downregulation of Ese-1/Esx is not
affected by SB-203580. It is possible that TGFβ does not
require Smad3/4 or p38 to inhibit Ese-1/Esx-expression.
Alternatively, inhibitory Smad7, whose expression was in-
creased by TGFβ but not affected by SB-203580, may be
involved in this process. One way by which Smad7 can in-
hibit TGFβ-dependent gene expression is by blocking
phosphorylation, and, hence, nuclear import of Smad3
and Smad2 [23]. More recent data showing that Smad7 is
able to interact with histone deacetylases suggest an addi-
tional role for Smad7 as a transcriptional co-repressor
[50]. Thus, Smad7 might interfere directly with Ese-1/Esx
gene transcription. However, TGFβ downregulated Ese-1/
Esx mRNA levels faster than it upregulated Smad7 expres-
sion excluding the possibility that Smad7 mediates the
TGFβ effect on Ese-1/Esx, at least at the initial phase. An-
other candidate that could be responsible for this process
is c-Jun N-terminal kinase (JNK). JNK has been described
to drive TGFβ-dependent fibronectin synthesis independ-
ent of Smad4 and p38 [51]. In contrast to Smad3, JNK is
activated by the TGFβ receptor I in a way that does not re-
quire the kinase domain [52]. This supports the notion
that activation of Smad3 and JNK by TGFβ are independ-
ent events. It is remarkable that a constitutively active
form of JNK activator MKK and Smad7 are able to cooper-
atively downregulate TGFβ-responsive promoters [53]. It
is quite possible that a Smad7/JNK synergistic interaction
is involved in the TGFβ-dependent downregulation of
Ese-1/Esx expression, where JNK alone might mediate the
initiation of the TGFβ-induced repression.
Conclusions
We demonstrate that treatment of invasive MDA-MB-231
breast cancer cells with SB-202190 and SB-203580 inter-
feres with TGFβ-induced Smad3 nuclear accumulation
and that this is paralleled by a differential transcriptional
response of TGFβ target genes. Strikingly, SB-202190 and
SB-203580 suppressed TGFβ-dependent activation of
those genes that are important for the acquisition of inva-
sive behavior, while having no effect on the expression of
the natural TGFβ inhibitor Smad7. This suggests that these
compounds may be useful to interfere with malignant be-
havior of cancer cells. Furthermore, we show for the first
time that, in breast cancer cells, the Ese-1/Esx mRNA is
downregulated by TGFβ.
Methods
Cell lines, plasmids and chemicals
MDA-MB-231 breast cancer cell line was maintained in
Dulbecco's modified Eagle's medium (Invitrogen) supple-
mented with 10% fetal calf serum (Invitrogen). The plas-
mid 3TP-Luc was kindly provided by Y. Sun. TGFβ1 was
purchased from R&D Systems and dissolved in 1 mg/ml
bovine serum albumine in 4 mM HCl as recommended by
the manufacturer. The inhibitors PD-98059, Y-27632, SB-
202190 and SB-203580 were obtained from Calbiochem
and dissolved in dimethyl sulfoxide.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/20
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Transient transfections and luciferase assay
Transient transfection of MDA-MB-231 breast cancer cells
has been described previously [19]. Briefly, 2 µg 3TP-Luc
together with 0.3 µg β-galactosidase expression plasmid
were transfected into cells grown to 70–80% confluency
in 6-well plates using LipofectAMINE reagent (Invitrogen)
following the manufacturers protocol. TGFβ stimulation
of cells (5 ng/ml) was performed 15 hours after transfec-
tion for the indicated times with or without preincubation
with the respective inhibitors. Control cells were treated
with the equivalent amount of TGFβ dissolving buffer (1
mg/ml bovine serum albumine in 4 mM HCl). Cells were
lysed and assayed for luciferase activity as described in
Blumenthal et al [20]. For calculation of relative promoter
activity, luciferase activity was normalized against β-galac-
tosidase activity.
Preparation of nuclear and whole cell extracts
Nuclear extracts were obtained as described elsewhere
[19]. Briefly, detached cells were resuspended in buffer A
(10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1
mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethyl-
sulfonyl fluoride) and cells were lysed with Nonidet P-40.
After centrifugation at 13000 rpm for 1 min, nuclei were
extracted by addition of buffer C (20 mM Hepes pH 7.9,
0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothre-
itol, 0.5 mM phenylmethylsulfonyl fluoride). Whole cell
extraction was performed by lysis of cells in 250 mM Tris-
Cl pH 7.5, three cycles of freezing and thawing and a sub-
sequent centrifugation step for 5 min at 13,000 rpm at
4°C. Total protein amount in the extracts was determined
using the Bio-Rad Bradford reagent.
Western Blot Analysis
Cell extracts were analysed by Western Blotting analysis as
reported previously [19]. Mouse anti-Smad3 (H-2) and
rabbit anti-PKC alpha (C-20) were purchased from Santa
Cruz Biotechnology and diluted 1:1000. Visualization of
protein bands was carried out using anti-IgG horseradish
peroxidase and ECL plus reagents from Amersham Phar-
macia Biotech.
Quantitative Real-Time RT-PCR
Isolation of total RNA and synthesis of cDNA were per-
formed as previously described [19]. RT-PCR reactions of
cDNAs were conducted in a total volume of 15 µl with 2
× Taqman Master Mix (Applied Biosystems) and primers
at optimized concentrations. Thermal cycler parameters
included 2 min at 50°C, 10 min at 95°C, and 40 cycles in-
volving denaturation at 95°C for 15 s and annealing/ex-
tension at 60°C for 1 min. Relative quantitation of gene
expression was determined using the comparative CT
method following the manufacturers guidlines. To deter-
mine the relative RNA levels of a particular gene, each CT
value was normalized against the CT value of a reference
RNA (18S rRNA). The following primers were used:
Ets-1: forward 5' CGTACGTCCCCCACTCCT 3'
reverse 5' TCCCATAGCAATGTCTAATTAATCTGG 3'
Ets-2 forward 5' TTTCTCATGACTCCGCCAACT 3'
reverse 5' GGCTTGACTCATCACAGCCTT 3'
Ese-1/ Esx forward 5' CAGGGCAGCTTGGAAGAG 3'
reverse 5' AAAAGCTTCTTGAAAGGAGACTTCTGT 3'
PTHrP Exon 2 forward 5' AGGAGGCGGTTAGCCCTG 3'
reverse 5' TCCCATAGCAATGTCTAATTAATCTGG 3'
c-myc forward 5' GTGCCACGTCTCCACACATC 3'
reverse 5' GCAGCAGGATAGTCCTTCCG 3'
Smad 7 forward 5' AAGGTGCGGAGCAAAAT 3'
reverse 5' TGTACACCCACACACCATCCA 3'
uPA forward 5' CTGCAGGAACCCAGACAACC 3'
reverse 5' GGACAAGCAGCTTTAGGCCC 3'
PAI-1 forward 5' GGCCATGGAACAAGGATGAGA 3'
reverse 5' GACCAGCTTCAGATCCCGCT 3'
18S rRNA forward 5' CGGCTACCACATCCAAGGAA 3'
reverse 5' GCTGGAATTACCGCGGCT 3'
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